Abstract
Objective
To assess the effect of neoadjuvant targeted molecular therapies (TMTs) on size and level of inferior vena cava tumor thrombi and to evaluate their impact on surgical management.
Methods
We retrospectively analyzed the data of 14 patients treated for a clear cell renal cell carcinoma with inferior vena cava thrombi by neoadjuvant TMT before nephrectomy. Clinical, pathological and perioperative data were gathered retrospectively at each institution. The primitive tumor size and the thrombus size were defined by computed tomography before TMT. The tumor thrombus level was defined according to the Novick’s classification.
Results
Before TMT, thrombus level was staged I for 1 (7 %), II for 10 (72 %) and III (21 %) for 3 patients. First-line therapy was sunitinib in 11 cases and sorafenib in 3 cases. Median therapy duration was two cycles (1–5). Three patients experienced major adverse effects (grade III) during TMT. Following TMT, 6 (43 %) patients had a measurable decrease, 6 (43 %) had no change, and 2 (14 %) had an increase in the thrombus. One patient (7 %) had a downstage of thrombus level, 12 (85 %) had stable thrombi, and 1 (7 %) had an upstage. Regarding primary tumor, 7 (50 %), 5 (36 %) and 2 (14 %) patients had a decrease, stabilization and an increase in tumor size, respectively.
Conclusion
Neoadjuvant TMT appears to have limited effects on renal tumor thrombi. This retrospective study failed to demonstrate a significant impact of neoadjuvant TMT on surgical management of clear cell renal cell carcinoma with inferior vena cava tumor thrombi.
Similar content being viewed by others
References
Kirkali Z, Van Poppel H (2007) A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol 52(3):658–662
Lawindy SM, Kurian T, Kim T, Mangar D, Armstrong PA, Alsina AE, Sheffield C, Sexton WJ, Spiess PE (2012) Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int 110(7):926–939
Parra J, Drouin SJ, Hupertan V, Comperat E, Bitker MO, Roupret M (2011) Oncological outcomes in patients undergoing radical nephrectomy and vena cava thrombectomy for renal cell carcinoma with venous extension: a single-centre experience. Eur J Surg Oncol 37(5):422–428
Rigaud J, Hetet JF, Braud G, Battisti S, Le Normand L, Glemain P, Karam G, Bouchot O (2006) Oncological results of renal cancer with inferior vena cava thrombosis after nephrectomy. Prog Urol 16(3):297–302
Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC, McKiernan JM (2007) Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology 69(6):1054–1058
Motzer RJ (2011) New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist 16(Suppl 2):1–3
Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK (2010) Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 28(9):1502–1507
Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181(2):518–523 [discussion 523]
Robert G, Gabbay G, Bram R, Wallerand H, Deminiere C, Cornelis F, Bernhard JC, Ravaud A, Ballanger P (2009) Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 55(6):1477–1480
Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P (2008) Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53(4):845–848
Cost NG, Delacroix SE, Jr., Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V (2011) The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59(6):912–918
Sobin LH GM, Wittekind C (eds) (2009) TNM classification of malignant tumors. UICC International union against cancer, 7th ed. Wiley-Blackwell, New York, pp 255–257
Novick AC (1989) Stewart’s operative urology, 2nd edn. Williams et Wilkins, Baltimore
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470
Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O’Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A (2011) A The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol 60(3):448–454
van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14(8):2431–2436
Chapin BF, Delacroix SE Jr, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG (2011) Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 60(5):964–971
Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J, Stockdale A, Rashid S, Nathan P, Chowdury S (2012) An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Eur J Cancer 48(17):3171–3176
Horn T, Thalgott MK, Maurer T, Hauner K, Schulz S, Fingerle A, Retz M, Gschwend JE, Kubler HR (2012) Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. Anticancer Res 32(5):1729–1735
Peters I, Winkler M, Juttner B, Teebken OE, Herrmann TR, von Klot C, Kramer M, Reichelt A, Abbas M, Kuczyk MA, Merseburger AS (2012) Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report. World J Urol [Epub ahead of print]
Conflict of interest
Authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bigot, P., Fardoun, T., Bernhard, J.C. et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?. World J Urol 32, 109–114 (2014). https://doi.org/10.1007/s00345-013-1088-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-013-1088-1